Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone

Brachytherapy

Volumn 9, Issue 4, 2010, Pages 341-348

  Wilder, Richard B ^a   Barme, Greg A ^a   Gilbert, Ronald F ^a   Holevas, Richard E ^a   Kobashi, Luis I ^a   Reed, Richard R ^a   Solomon, Ronald S ^a   Walter, Nancy L ^a   Chittenden, Lucy ^a   Mesa, Albert V ^a   Agustin, Jeffrey K ^a   Lizarde, Jessica ^a   Macedo, Jorge C ^a   Ravera, John ^a   Tokita, Kenneth M ^a  

^a Cancer Center of Irvine   (United States)

Author keywords

Brachytherapy; Cancer; HDR; IMRT; Prostate

Indexed keywords

SILDENAFIL; TAMSULOSIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CYSTITIS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE FREE SURVIVAL; FOLLOW UP; HIGH DOSE RATE BRACHYTHERAPY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME; URETHRA STRICTURE; URINE INCONTINENCE; URINE RETENTION;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; GOLD; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RISK FACTORS;

EID: 77957374831     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2009.08.003     Document Type: Article

References (48)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 2006, 7:355-362.
3. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998, 41:501-510.
4. Jani A.B., Su A., Correa D., et al. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 2007, 10:82-86.
5. Zelefsky M.J., Cowen D., Fuks Z., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999, 85:2460-2468.
6. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000, 55:241-249.
7. Al-Salihi O., Mitra A., Payne H. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy. Prostate Cancer Prostatic Dis 2006, 9:370-373.
8. Fang F.M., Wang Y.M., Wang C.J., et al. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Jpn J Clin Oncol 2008, 38:474-479.
9. Kotte A.N., Hofman P., Lagendijk J.J., et al. Intrafraction motion of the prostate during external-beam radiation therapy: Analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 2007, 69:419-425.
10. Mansson Haska T., Honore H., Muren L.P., et al. Intrafraction changes of prostate position and geometrical errors studied by continuous electronic portal imaging. Acta Oncol 2008, 47:1351-1357.
11. Hoskin P.J., Motohashi K., Bownes P., et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol 2007, 84:114-120.
12. Pieters B.R., van de Kamer J.B., van Herten Y.R., et al. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 2008, 88:46-52.
13. Lips I.M., Dehnad H., van Gils C.H., et al. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: Acute and late toxicity in 331 patients. Radiat Oncol 2008, 3:15.
14. Hoskin P. High dose rate brachytherapy for prostate cancer. Cancer Radiother 2008, 12:512-514.
15. Kiffer J.D., Schumer W.A., Mantle C.A., et al. Impact of oedema on implant geometry and dosimetry for temporary high dose rate brachytherapy of the prostate. Australas Radiol 2003, 47:172-176.
16. Soumarova R., Homola L., Perkova H., et al. Three-dimensional conformal external beam radiotherapy versus the combination of external radiotherapy with high-dose rate brachytherapy in localized carcinoma of the prostate: Comparison of acute toxicity. Tumori 2007, 93:37-44.
17. Goffinet D.R., Martinez A., Freiha F., et al. 125Iodine prostate implants for recurrent carcinomas after external beam irradiation: Preliminary results. Cancer 1980, 45:2717-2724.
18. Kucway R., Vicini F., Huang R., et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002, 167:2443-2447.
19. Thompson A., Fox C., Foroudi F., et al. Planning and implementing an implanted fiducial programme for prostate cancer radiation therapy. J Med Imaging Radiat Oncol 2008, 52:419-424.
20. Vetterli D., Thalmann S., Behrensmeier F., et al. Daily organ tracking in intensity-modulated radiotherapy of prostate cancer using an electronic portal imaging device with a dose saving acquisition mode. Radiother Oncol 2006, 79:101-108.
21. Roberts T., Roach M. The evolving role of pelvic radiation therapy. Semin Radiat Oncol 2003, 13:109-120.
22. Hsu A., Pawlicki T., Luxton G., et al. A study of image-guided intensity-modulated radiotherapy with fiducials for localized prostate cancer including pelvic lymph nodes. Int J Radiat Oncol Biol Phys 2007, 68:898-902.
23. Fowler J.F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005, 44:265-276.
24. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
25. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
26. Lee W.R., DeSilvio M., Lawton C., et al. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: Preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys 2006, 64:804-809.
27. Jager K.J., van Dijk P.C., Zoccali C., et al. The analysis of survival data: The Kaplan-Meier method. Kidney Int 2008, 74:560-565.
28. Zhang D., Quan H. Power and sample size calculation for log-rank test with a time lag in treatment effect. Stat Med 2009, 28:864-879.
29. Cassidy L.D. Basic concepts of statistical analysis for surgical research. J Surg Res 2005, 128:199-206.
30. Freedland S.J., Presti J.C., Terris M.K., et al. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: Results from the SEARCH database. J Urol 2003, 169:2129-2135.
31. Buyyounouski M.K., Horwitz E.M., Hanlon A.L., et al. Positive prostate biopsy laterality and implications for staging. Urology 2003, 62:298-303.
32. Greene K.L., Elkin E.P., Karapetian A., et al. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: Results from CaPSURE. J Urol 2006, 175:125-129. discussion 129.
33. Liebross R.H., Pollack A., Lankford S.P., et al. Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy. Urology 1998, 52:647-652.
34. Wu I., Nielsen M.E., Han M., et al. Does laterality of positive needle biopsy in clinical T2a patients with prostate cancer affect biochemical recurrence-free survival?. Urology 2008, 72:1219-1223.
35. Milecki P., Kwias Z., Martenka D.J. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: Perspective and therapeutic gain analysis. Neoplasma 2007, 54:7-15.
36. Cahlon O., Zelefsky M.J., Shippy A., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008, 71:330-337.
37. Grills I.S., Martinez A.A., Hollander M., et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004, 171:1098-1104.
38. Vargas C., Ghilezan M., Hollander M., et al. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. J Urol 2005, 174:882-887.
39. Fujioka H., Ishimura T., Sakai Y., et al. Erectile function after brachytherapy with external beam radiation for prostate cancer. Arch Androl 2004, 50:295-301.
40. Bachand F., Martin A.G., Beaulieu L., et al. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: Biopsy and PSA outcome. Int J Radiat Oncol Biol Phys 2009, 73:679-684.
41. Chen Y.C., Chuang C.K., Hsieh M.L., et al. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: An experience in Taiwan. Urology 2007, 70:101-105.
42. Vargas C.E., Martinez A.A., Boike T.P., et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a phase I to II study. Int J Radiat Oncol Biol Phys 2006, 66:416-423.
43. Yamada Y., Bhatia S., Zaider M., et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy 2006, 5:157-164.
44. Prada P.J., Gonzalez H., Fernandez J., et al. High-dose-rate intensity modulated brachytherapy with external-beam radiotherapy improves local and biochemical control in patients with high-risk prostate cancer. Clin Transl Oncol 2008, 10:415-421.
45. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:1048-1055.
46. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005, 61:1306-1316.
47. Ghadjar P., Vock J., Vetterli D., et al. Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. Radiat Oncol 2008, 3:35.
48. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002, 53:1111-1116.